Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

These hormones have several functions. For example, they: In people with type 2 diabetes, incretin levels are absent or lower than they should be. Peptide medications, like GLP-1 and GLP-1/GIP ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

Some of the “anti-ageing” benefits seen with GLP1RAs may simply be the result of their weight-loss inducing properties.

Reduction in body weight can prevent, delay or reduce the development of these conditions with advancing age. GLP-1RAs, ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 ...

Deliver a fourth IND candidate in 2025 based on the Biomea FUSION™ Platform technology. Cash, Cash Equivalents, and Restricted Cash: As of September 30, 2024, the Company had cash, cash equivalents ...

We are pleased to announce the advancement of our third clinical development candidate – a next-generation oral small molecule GLP-1 receptor agonist. Incretins have become the backbone of ...